125 related articles for article (PubMed ID: 28258630)
1. Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo.
Wu SW; Chen PN; Lin CY; Hsieh YS; Chang HR
Environ Toxicol; 2017 Jul; 32(7):1888-1898. PubMed ID: 28258630
[TBL] [Abstract][Full Text] [Related]
2. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
4. Kaempferol Inhibits the Invasion and Migration of Renal Cancer Cells through the Downregulation of AKT and FAK Pathways.
Hung TW; Chen PN; Wu HC; Wu SW; Tsai PY; Hsieh YS; Chang HR
Int J Med Sci; 2017; 14(10):984-993. PubMed ID: 28924370
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
6. EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.
Cho MC; Cho SY; Yoon CY; Lee SB; Kwak C; Kim HH; Jeong H
PLoS One; 2015; 10(7):e0130975. PubMed ID: 26177500
[TBL] [Abstract][Full Text] [Related]
7. Rubus idaeus L. reverses epithelial-to-mesenchymal transition and suppresses cell invasion and protease activities by targeting ERK1/2 and FAK pathways in human lung cancer cells.
Hsieh YS; Chu SC; Hsu LS; Chen KS; Lai MT; Yeh CH; Chen PN
Food Chem Toxicol; 2013 Dec; 62():908-18. PubMed ID: 24161487
[TBL] [Abstract][Full Text] [Related]
8. Antimetastatic effects of gossypol on colon cancer cells by targeting the u-PA and FAK pathways.
Huang SF; Chu SC; Hsu LS; Tu YC; Chen PN; Hsieh YS
Food Funct; 2019 Dec; 10(12):8172-8181. PubMed ID: 31730141
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid inhibits epithelial‑mesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression.
Mao S; Lu G; Lan X; Yuan C; Jiang W; Chen Y; Jin X; Xia Q
Mol Med Rep; 2017 Nov; 16(5):6190-6199. PubMed ID: 28901475
[TBL] [Abstract][Full Text] [Related]
11. 3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Lu KH; Chen PN; Hsieh YH; Lin CY; Cheng FY; Chiu PC; Chu SC; Hsieh YS
Food Chem Toxicol; 2016 Nov; 97():177-186. PubMed ID: 27600294
[TBL] [Abstract][Full Text] [Related]
12. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism.
Ho MY; Tang SJ; Chuang MJ; Cha TL; Li JY; Sun GH; Sun KH
Mol Cancer Res; 2012 Aug; 10(8):1109-19. PubMed ID: 22707636
[TBL] [Abstract][Full Text] [Related]
13. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.
Akaza H; Kurihara R; Katsura A; Harumiya M; Ushida N
Jpn J Clin Oncol; 2019 Oct; 49(10):956-964. PubMed ID: 31135920
[TBL] [Abstract][Full Text] [Related]
14. Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway.
Tsai YM; Yang CJ; Hsu YL; Wu LY; Tsai YC; Hung JY; Lien CT; Huang MS; Kuo PL
Integr Cancer Ther; 2011 Dec; 10(4):341-9. PubMed ID: 21059620
[TBL] [Abstract][Full Text] [Related]
15. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
16. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
17. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.
Bracarda S; Rottey S; Bahl A; Eichelberg C; Mellado B; Mangel L; Cattaneo A; Panneerselvam A; Grünwald V
Future Oncol; 2015; 11(21):2893-903. PubMed ID: 26376939
[TBL] [Abstract][Full Text] [Related]
18. Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.
Piva F; Giulietti M; Santoni M; Occhipinti G; Scarpelli M; Lopez-Beltran A; Cheng L; Principato G; Montironi R
Mol Diagn Ther; 2016 Apr; 20(2):111-7. PubMed ID: 26940073
[TBL] [Abstract][Full Text] [Related]
19. Role of WNT/β-Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Chrom P; Szczylik C
Clin Genitourin Cancer; 2018 Aug; 16(4):257-265. PubMed ID: 29483043
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
